- Company
- Bonviva generics dodge a bullet from patent dispute
- by Kim, Jin-Gu Mar 26, 2021 05:38am
- The generic makers won the patent dispute over an antiarthritis Bonviva (ibandronate) and now they are finally free from the risk of sales ban and damage compensation. According to the pharmaceutical industry source on Mar. 23, the Intellectual Property Trial and Appeal Board issued a trial decision that the dosage regimen patent for Bon
- Company
- Problems with the most expensive CAR-T treatment Kymriah
- by Mar 26, 2021 05:38am
- The CAR-T treatment Kymriah (Tisagenlecleucel), which is considered the hope of terminal blood cancer patients, was launched in Korea after 4 years, but there are problems to be solved. Kymriah is treated in a completely different way from existing medicines, so it is not easy to calculate the drug price, and at a price of &8361;500 milli
- Policy
- Drug price management office takes care of all drug prices
- by Lee, Hye-Kyung Mar 26, 2021 05:37am
- “Drug Price Management Office of the NHIS is in charge of practical work to apply the results of research services for full-cycle management of pharmaceuticals to the field. It reviews and tries to realize the improvement or reform of the system related to pharmaceuticals. " Kang Cheong-hee, the executive director of the NHIS’ benefit re
- Company
- Samchundang to start oral insulin clinical trial this year
- by Kim, Jin-Gu Mar 26, 2021 05:37am
- Samchundang Pharm announced its plan to start clinical trial on 'oral insulin' within this year. Also the South Korean company explained that four vaccines were added to the pipeline of the 'S-Pass' platform, a technology converting injection into oral drug. In the case of Eylea (aflibercept) biosimilar, the company expects to complete a
- Policy
- Lipilouzet, listed as the highest price for the same formula
- by Kim, Jung-Ju Mar 26, 2021 05:37am
- Lipilouzet, a combination drug of Chong Kun Dang's Atorvastatin Calcium + Ezetimibe, will be listed as the highest price for the same formulation of all combinations. Pfizer Korea's Xeljanz XR Tab 11mg (Tofacitinib Citrate) does not have the same formulation, so it is listed at the same price as the target product. The MOHW is promoting the revi
- InterView
- “Amgen knows how to do it right in Korea”
- by Eo, Yun-Ho Mar 25, 2021 05:59am
- Amgen knows the game in the industry. Besides the title of the ‘Number One Global Bio Company,’ Amgen Korea knows how to be versatile in South Korea. Since opening the South Korean office in 2015, Amgen listed all six products&8212;antiarthritis Prolia (denosumab) and Evenity (romosozumab), skeletal-related events preventing drug Xg
- Policy
- Reduced drug price by expanding the scope of Abraxane
- by Kim, Jung-Ju Mar 25, 2021 05:58am
- Celgene's anticancer drug Abraxane (Paclitaxel) is expected to cut the drug price by 3.6% next month as the scope of use is expanded. Janssen Korea's prostate cancer treatment Zytiga 500mg (Abiraterone Acetate) is subject to a 5% cut rate due to an additional indication, and advance drug price cuts are being promoted. Takeda Pharmaceutical Ko
- Policy
- MOHW announces list of premium pricing benefit decision
- by Kim, Jung-Ju Mar 25, 2021 05:58am
- The South Korean health authority is to authorize 30-percent reimbursed pricing reduction in every dose of Eisai Korea’s Symbenda injection (bendamustine hydrochloride). After a year, the injection’s pricing would be brought down again by 23.5 percent due to the expired weighted pricing benefit. Novartis Korea’s Afinitor (everolimus) is to ma
- Company
- The patent dispute for the combination drug Ducarb expanded
- by Kim, Jin-Gu Mar 25, 2021 05:58am
- The patent challenges of 34 domestic companies for Boryung's Dukarb are following one after another. It is analyzed that the expiration of the substance patent of Fimasartan is approaching two years in the future, and it is aiming for the early release of generics for combination drugs including Fimasartan. According to the pharmaceutical
- Opinion
- [Editor’s View] One year after the pandemic
- by Chon, Seung-Hyun Mar 25, 2021 05:58am
- A year has passed since COVID-19 hit the world. About this time last year, when the World Health Organization (WHO) declared a global pandemic of COVID-19, the KOSPI index dropped to the 1400 line. But suddenly, the KOSPI index recovered to 3000. On March 19 of last year, the KRX healthcare index, composed of major pharmaceutical and bio
